Table 1.
FDA-approved immune checkpoint inhibitors.
| Name | Company | Target | Indications * |
|---|---|---|---|
| Ipilimumab (Yervoy®) | Bristol-Myers Squibb, New York, U.S.A. | CTLA-4 | Melanoma, RCC, colorectal cancer, HCC, NSCLC, malignant pleural mesothelioma |
| Pembrolizumab (Keytruda®) | Merck Co., New Jersey, U.S.A. | PD-1 | Melanoma, NSCLC, SCLC, HNSCC, urothelial carcinoma, primary mediastinal large B-cell lymphoma, gastric cancer, cervical cancer, esophageal cancer, TNBC, hepatocellular carcinoma, MCC, RCC, endometrial carcinoma, cutaneous squamous cell carcinoma, tumor mutational burden-High cancer, microsatellite instability or mismatch repair deficient colorectal cancer, microsatellite instability-High cancer |
| Nivolumab (Opdivo®) | Bristol-Myers Squibb, New York, U.S.A. | PD-1 | Melanoma, RCC, NSCLC, SCLC, cHL, HNSCC, HCC, colorectal cancer, urothelial carcinoma, esophageal squamous cell carcinoma |
| Cemiplimab (Libtayo®) | Sanofi, Paris, France | PD-1 | Cutaneous squamous cell carcinoma |
| Atezolizumab (Tecentriq®) | Roche, Basel, Switzerland | PD-L1 | Urothelial carcinoma, NSCLC, TNBC, SCLC, HCC, melanoma |
| Avelumab (Bavencio®) | Pfizer, New York, U.S.A. and Merck, U.S.A. | PD-L1 | Metastatic MCC, metastatic urothelial carcinoma |
| Durvalumab (Imfinzi®) | AstraZeneca, Cambridge, U.K. | PD-L1 | Advanced or metastatic urothelial carcinoma, stage III NSCLC |
* RCC: Renal cell carcinoma, HCC: Hepatocellular carcinoma, NSCLC: Non-small cell lung cancer, SCLC: Small cell lung cancer, HNSCC: Head and neck squamous cell cancer, cHL: classical Hodgkin Lymphoma, TNBC: Triple negative breast cancer, MCC: Merkel cell carcinoma.